Kingdom Supercultures
-78%
est. 2Y upside i
Kingdom Supercultures is a fast-growing biotech startup that helps consumer goods manufacturers make products that are more natural, healthy, and sustainable. They are building an innovative platform to collect, characterize, and assemble natural microbes into new combinations (“Supercultures”), which are used by customers to make plant-based cheeses with authentic dairy tastes, lower-alcohol wines with full flavor, personal care products with natural functional ingredients, and much more.
Rank
#3886
Sector
Biotech
Est. Liquidity
~5Y
Data Quality
Data: LowEquity upside appears highly negative under all scenarios due to stale valuation and high incumbent threat.
Last updated: July 3, 2026
FDA GRAS approval and category leadership support 8x multiple; projected revenue $9.8M implies $78.6M exit, but entry $100M and 20% dilution yield -41%.
Multiple converges to 5x public comps; $49.1M exit after 20% dilution yields -71% from $100M entry.
Multiple contracts to 3x; $29.5M exit is below $30M preference stack, common stock recovers nothing.
Preference Stack Risk
highFunding Intensity
2780%Total $30M funding is 30% of assumed $100M valuation; 1x non-participating preferred.
Dilution Risk
highLikely need additional raise within 2 years; estimated 20% dilution.
Secondary Liquidity
noneNo secondary market or signals.
Questions to Ask at the Interview
Strategic questions based on Kingdom Supercultures's data — designed to show you've done your homework.
- 1
“How do you compete against large incumbents like IFF and DSM given your small scale?”
- 2
“What is the revenue growth trajectory and when do you expect to be profitable?”
- 3
“What is the current fair value and when is the next liquidity event expected?”
Community
Valuation Sentiment
Our model estimates -78% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.